M.GrossbachA
Seek emergency help immediately (call 999) if, after using any unlicensed peptide compound, you experience any of the following life-threatening symptoms: Signs of anaphylaxis: rash, swelling of the face, lips, or throat, difficulty breathing, or sudden collapse Severe chest pain or palpitations Signs of serious infection (sepsis): high fever, confusion, rapid breathing, or mottled skin following an injection Contact NHS 111 for urgent advice (when symptoms are not immediately life-threatening) if you experience: Persistent or severe nausea, vomiting, or abdominal pain Signs of infection at an injection site: increasing redness, warmth, swelling, pus, or fever Dizziness, fainting, or unexplained changes in blood glucose or metabolic function It is also advisable to inform your GP if you are using or considering any research peptides, even if you feel well
26 Recently, mitapivat and etavopivat (Figure 3) were developed as oral allosteric activators to bind a pocket at the dimer-dimer interface distinct from the FBP-binding domain
106404, Merck, Darmstadt, Germany), 2.5 mM calcium chloride (CaCl 2
